

UCSF

UC San Francisco Previously Published Works

Title

Efficacy of thermal ablation for treatment of biopsy-confirmed high-grade cervical precancer among women living with HIV in Kenya.

Permalink

<https://escholarship.org/uc/item/65c8v71n>

Journal

International Journal of Cancer, 153(12)

Authors

Mungo, Chemtai
Osongo, Cirilus
Ambaka, Jeniffer
[et al.](#)

Publication Date

2023-12-15

DOI

10.1002/ijc.34737

Peer reviewed



Published in final edited form as:

Int J Cancer. 2023 December 15; 153(12): 1971–1977. doi:10.1002/ijc.34737.

Efficacy of thermal ablation for treatment of biopsy-confirmed high-grade cervical precancer among women living with HIV in Kenya

Chemtai Mungo, MD, MPH¹, Cirilus Ogollah Osongo, BSc, DipCM², Jeniffer Ambaka, DipCM², Jackton Omoto, MBChB, M.Med³, Craig R. Cohen, MD, MPH⁴

¹Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

²Kenya Medical Research Institute, Kisumu, Kenya

³Department of Obstetrics and Gynecology, Maseno University School of Medicine, Kisumu, Kenya

⁴Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California, USA

Abstract

The World Health Organization recommends thermal ablation (TA) as an alternative to cryotherapy within “screen-and-treat” cervical cancer programs in low- and middle-income countries (LMICs), including among women living with HIV (WLWH). Data on TA efficacy among WLWH are limited, however. We conducted a clinical trial to evaluate efficacy of TA for treatment of biopsy-confirmed cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3) among WLWH in Kenya. Non-pregnant HPV-positive WLWH age 25–65 years underwent colposcopy-directed biopsy, and same-day treatment with TA, if eligible. Women with biopsy-confirmed CIN2/3 at baseline had colposcopy-directed biopsies at 12-months to determine cure. A total of 376 participants underwent TA during the study period. At baseline, 238 (63.3%) had normal histology, 39 (10.4%) had CIN1, 15 (4.0%) had CIN2, 55 (14.6%) had CIN3, 7 (1.9%) had microinvasive cancer, and 22 (5.6%) had indeterminate results. Twelve-month follow-up pathology results are available for 59 of 70 (84.3%) participants with CIN2/3 at baseline. Of these, 39 (66.1%, 95% CI 0.54–0.99) had successful treatment, defined as biopsy-confirmed CIN1 or normal findings, while 20 (33.9%, 95% CI 0.22–0.46) had treatment failure, defined as persistent biopsy-confirmed CIN2 or worse. Treatment failure was 23.1% (95% CI 0.17 – 0.46) and 39.9%

Corresponding author: Dr. Chemtai Mungo, Division of Obstetrics and Gynecology, University of North Carolina-Chapel Hill, Chapel Hill, NC, 3009 Old Clinic Building, Box 7570, Chapel Hill, NC 27599, Chemtai_mungo@med.unc.edu, Twitter: @ChemtaiMungo.

Author Contributions: CM and CRC conceptualized the project, CM, COO, JA and JO led study implementation, CM performed analysis and wrote original draft, JO, CRC aided in interpreting the results and revised the manuscript. All authors discussed the results and commented on the manuscript. The work reported in the paper has been performed by the authors, unless clearly specified in the text.

Ethics Statement: The trial was registered under [ClinicalTrials.gov](https://clinicaltrials.gov) identifier: [NCT04191967](https://clinicaltrials.gov/ct2/show/study/NCT04191967). Ethics approval for the study was obtained from the institutional review boards of Maseno University and the University of California San Francisco. All participants provided written informed consent.

Conflict of Interest: The authors have no conflict of interest to disclose.

(95% CI 0.23–0.51) among women with CIN2 and CIN3 at baseline, respectively. HIV-positive women with CIN2/3 have high rates of treatment failure at 1-year following thermal ablation. This highlights a significant limitation in the current WHO cervical cancer secondary-prevention strategy and calls for strategies to optimize cervical precancer treatment in this population.

Keywords

thermal ablation efficacy; women living with HIV; CIN2/3; low- and middle-income countries (LMICs)

Background

Cervical cancer incidence and mortality data demonstrate a dire global health inequity. Despite being preventable, in 2020, low-and middle-income countries (LMICs) accounted for 85% of the estimated 570,000 incident cervical cancer cases and 90% of deaths globally.¹ The burden of cervical cancer is particularly pronounced in sub-Saharan Africa (SSA) where HIV is endemic.² Women living with HIV (WLWH) have a higher incidence and persistence of human papillomavirus (HPV), the causative agent of cervical cancer, and a six-fold increased risk of developing cervical cancer.² As such, cervical cancer prevention among WLWH is an urgent priority.

In 2013, the World Health Organization (WHO) recommend use of cryotherapy for cervical precancer treatment within screen & treat programs in LMICs.³ However, large-scale implementation of cryotherapy is hindered by challenges of transporting bulky gas cylinders and maintaining a consistent supply of refrigerant gas, especially in rural areas.⁴ In Malawi, cryotherapy delivery challenges led to only 43.3% of screen-positive women getting treatment in a five-year period.⁴ This led to a search for more feasible treatment options. In 2019, the WHO recommended use of thermal ablation (TA) as an alternative to cryotherapy for use within screen-and-treat programs in LMICs.⁵ Similar to cryotherapy, TA does not require anesthesia and can be nurse-administered, ideal for LMICs' primary care settings. TA battery-powered devices are lightweight (2–5 kg) and portable, unlike heavy cryotherapy gas cylinders (15–20 kg), making it more feasible for use in remote clinics.⁴ With similar WHO treatment eligibility criteria, TA is increasingly replacing cryotherapy in LMICs' cervical cancer prevention programs.

However, high-quality data on the efficacy of thermal ablation for treatment of cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3) – the precancerous lesion most likely to progress to cervical cancer - among WLWH are lacking. Available TA efficacy data are primarily from high-income countries with low HIV-prevalence, and where desktop-based rather than handheld thermal ablation devices have been used for treatment.^{6,7} In a 2019 meta-analysis of available TA efficacy evidence from 23 studies, the cure rate for CIN2/3 was 93.9%.⁶ However, only five studies included WLWH. Two of these studies were done in SSA^{8,9} and neither used biopsy-confirmed disease – the gold standard, to define cervical precancer cases or to evaluate cure. Instead, visual inspection with acetic acid (VIA) which is known to be highly subjective and non-specific,¹⁰ was used. The lack of robust TA efficacy data among WLWH in LMICs led the WHO to issue a conditional recommendation,

citing “low-to moderate evidence” in this population.⁵ To address this gap in the literature, we evaluate the efficacy of thermal ablation for treatment of biopsy-confirmed CIN2/3 among WLWH in Kenya, a low- and middle-income country in SSA.

Methods

We conducted a single-arm clinical trial at Lumumba Sub-County Hospital within a President’s Emergency Plan for AIDS Relief (PEPFAR)-supported HIV clinic in Western Kenya. Between August 2019 to December 2021, WLWH age 25–65 years were offered cervical cancer screening using careHPV, which tests for DNA of 14 high-risk HPV types. HPV-positive, non-pregnant women without a history of cervical cancer or precancer treatment were eligible to participate. Per study protocol, all HPV-positive women eligible for ablation were offered TA on the same day regardless of whether a lesion was seen on VIA. Women were considered candidates for TA per the WHO criteria – if, following application of acetic acid, the squamocolumnar junction was fully visualized, cervical lesions, if present, covered less than 75% of the cervix, and there was no endocervical component of the lesion or suspicion for cancer.³ Ineligible women were referred for excision or other evaluation by a gynecologist. Prior to ablation, all women underwent colposcopically directed biopsies of abnormal lesions, or in the absence of lesions on colposcopy, a random biopsy at 6 or 12 o’clock for disease status ascertainment. The Liger device (Cure Medical Global, USA) was used for TA, applying either a single flat probe for type 1 transformation zone, or nipple shaped probe for type 2 transformation zone, heated to 100⁰C. Treatment lasted 20 seconds per application, with multiple applications if needed to cover the lesion, as previously described.¹¹ Cervical biopsies were read by a registered pathologist at the University of Nairobi using the WHO 3-tiered CIN classification.¹² Women with microinvasive cancer at baseline were referred for care, and those with indeterminate results offered repeat screening. Participants CIN2/3 at baseline had 12-months follow-up with and repeat colposcopy, with biopsies of visible lesions or a random biopsy if no lesion was present to assess cure.

Data were analyzed using Stata version 13.1 (StataCorp, Texas, USA). Treatment efficacy was defined as the proportion with CIN2/3 at baseline who had biopsy-confirmed CIN1 or normal pathology at follow-up. Univariate analysis was performed to investigate the association between treatment efficacy at follow-up and clinical and demographic variables at baseline. The Wilcoxon Rank-Sum test was used to investigate the relationship between CD4 count at baseline and CIN2/3 persistence.

Results

Three hundred and seventy-six participants were consented and enrolled in the study (Figure 1). At baseline histology 238 (63.3%) participants had normal findings on pathology, 39 (10.4%) had CIN1, 70 (18.4%) had CIN2/3, 7 (1.9%) had microinvasive cervical cancer, while 22 (5.9%) had indeterminate results. Participants with microinvasive disease were referred for treatment. Of the 70 participants with CIN2/3 at baseline, 59 (84.3%) were seen at 12-month follow-up with histology available, while 11 (15.7%) were either lost to follow-up or had no histology available.

The demographic and clinical characteristics of participants with less than CIN2 at baseline (n=299) are compared to those with CIN2 or worse (n=77) in Table 1. The mean age was 39.9 years among those with less than CIN2, and 40.5 years among those with CIN2 or worse. The mean CD4 cell count did not differ between the groups and was greater than 400 cell/mm³ and both groups had ~97% HIV viral suppression at baseline. Compared to participants with < CIN2, participants with CIN2 or worse were more likely to be VIA positive (11.3% versus 0.9%, p<0.0001) and to require more than 1 probe application to treat their lesion (27.3% vs 17.1%, p=0.003).

The mean time to follow-up was 14.4 months (SD 2.3). Among the 59 (84.3%) participants with CIN2/3 at baseline who were seen at follow-up, 39 (66.1%, 95% CI 0.54–0.99) had successful treatment, with follow-up pathology of CIN1 or less, while 20 (33.9%, 95% CI 0.22–0.46) had treatment failure, defined as CIN2 or worse on pathology (Table 2). Treatment failure was 23.1% (95% CI 0.17 – 0.46) and 39.9% (95% CI 0.23–0.51) among women with CIN2 and CIN3 at baseline, respectively. The 3 participants with CIN2 at baseline who failed treatment all progressed to CIN3 at 12-months. Of the 17 with CIN3 at baseline who failed treatment, 2 had CIN2 at follow-up while 15 had persistent CIN3. In univariate analysis, no demographic or clinical variables were significantly associated with CIN2/3 treatment failure at follow-up (data not shown). While not statistically significant, compared to those with baseline CD4 count < 200 cell/mm³, participants with CD4 greater than 200 were less likely to have treatment failure, OR 0.6 (95% CI 0.11–3.34). Participants who had a detectable viral load had 1.2 increased odds of treatment failure compared to those with viral suppression (95% CI 0.11–32.01), and those with CIN3 had 1.95 increased odds of treatment failure compared to those with CIN2 at baseline (95% CI 0.47–8.1).

Discussion

In this study evaluating the efficacy of TA for treatment of biopsy-confirmed high-grade cervical precancer (CIN2/3) among HPV-positive WLWH in Kenya, the rates of CIN2/3 treatment failure at 12-months are high. Treatment failure was highest for women with CIN3 at baseline, with over a third found with CIN2 or worse at 12-months. At baseline, all women were enrolled in HIV care and on antiretroviral therapy with good disease control as evidenced by a mean CD4 count of 473 cell/mm³ and with over 95% having HIV viral suppression. To our knowledge, this is the first study to report the efficacy of TA for treatment of CIN2/3 in HPV-positive WLWH from SSA with rigorous disease status ascertainment at both baseline and follow-up.

Thermal ablation was endorsed by the WHO in 2019 for use within screen-and-treat programs in LMICs, including among WLWH, in part to address challenges with implementation of cryotherapy. Previous TA efficacy studies, primarily from high-income, low HIV prevalence countries and using desktop-based devices, report high CIN2/3 efficacy rates.^{7,13,14} In the largest systematic review, TA had 93.8% efficacy for treatment of biopsy confirmed CIN2/3.⁶ However, generalizability of these results to WLWH in SSA are limited due to lack of rigorous efficacy data from this population.

Our findings of high CIN2/3 treatment failure rates align with recent TA efficacy studies using hand-held devices, which also assessed disease status in WLWH through histology or other objective criteria.^{15–17} In a 2023 study reporting 3.5-year treatment outcomes from a cohort of WLWH in India, among 32 HPV+ WLWH with biopsy-confirmed CIN2/3 who received TA and had follow-up, 9 (28%) had persistent CIN2+ at follow-up.¹⁵ Although data on the impact of HIV control on CIN treatment outcome was not reported, persistent HPV infection following TA was significantly associated with recurrent CIN2/3 (OR 138.2, 95% CI 20.3–3300.2). In a 2020 study reporting pilot results of an ongoing randomized trial in Zambia, treatment success following TA, defined as type-specific HPV clearance at 6-months was 44% in WLWH, compared to 83% in HIV-negative women.¹⁶ Despite the limitation of no histological diagnosis at baseline for direct comparison, the high persistent HPV rates post-TA observed in WLWH is a known risk factor of CIN2/3 treatment failure,¹⁸ and suggests TA's limitation in WLWH. Among HIV-negative women in SSA, higher than previously reported TA failure rate for women with biopsy-confirmed CIN2/3 was demonstrated in a study from Cameroon in which 29.4% with biopsy-confirmed CIN2/3 had persistent disease 12-months after thermal ablation.¹⁷ In this study, presence of occult endocervical lesions and first sexual activity before 15 years of age were significantly associated with treatment failure. Our results are also consistent with prior randomized trials using histology diagnosis from South Africa¹⁹ and Kenya²⁰ that demonstrate 27% - 30% CIN2/3 recurrence in WLWH at 12–24 months following cryotherapy, further demonstrating limitations of ablation in WLWH. The association of high HIV viral load and low CD4 cell counts with CIN2/3 treatment failure, which is suggested in our results, has been observed in other studies.²⁰

The demonstrated high CIN2/3 treatment failure rate in WLWH is concerning as TA is increasingly the main precancer treatment method used in SSA where access to excision is limited. Without robust follow-up, which is often lacking in many LMICs, many treated women are at risk of progression to invasive cancer where curative options are limited or unavailable. As such, studies aimed at understanding the causes of CIN2/3 treatment failure following TA in WLWH are urgently needed. This includes the impact of TA treatment duration on depth of tissue necrosis and hence treatment adequacy, appropriate patient selection for TA in screen & treat programs, the impact of probes type used on treatment efficacy, among other factors. The WHO guidelines recommends a minimum of 20–30 seconds per TA treatment application,⁵ and prior studies primarily in HIV-negative women suggest no difference in cure rates by treatment length.⁶ Among women undergoing hysterectomy for benign conditions, the mean depth of tissue destruction following TA ranged from 2.6 mm (100°C for 20 seconds) to 3.5 mm (120°C for 30 seconds).²¹ However, the maximal depth of CIN2/3 lesions in under-screened women in LMICs may be deeper, as was demonstrated in a study in Peru where 10.3% of cone excision specimens for CIN3 had depth 3.5mm.²² This suggests that the depth of necrosis following 20 or 30 second TA treatment may not achieve sufficient therapeutic depth in certain women, and this may contribute to the high recurrence observed. There are no published studies on the depth of CIN2/3 necrosis based on duration of TA among WLWH in SSA.

Data on whether use of the '2-probe technique' may impact TA efficacy in WLWH are also lacking. The 2-probe technique, used in the initial TA studies and associated with high

CIN2/3 treatment efficacy rates involves using a conical probe to ablate the lower (distal) endocervical canal, followed by a flat probe to ablate the entire visible transformation zone.¹³ Standard guidelines do not currently exist on use of different probes types, and none of the handheld TA devices used in LMICs have an separate endocervical probe. In our study, a single probe with a small nipple was used for Type 2 transformation zones and a flat probe for Type 1 transformation zones. It is unknown whether use of a separate conical probe to ablate the endocervix would impact recurrence in WLWH, and this can be explored in future studies. Possible reasons this 2-probe technique may be more effective includes potentially ablating distant endocervical crypts²³ removed from the transformation zone that harbor HPV-infected or dysplastic cells. In a U.K study among HIV-negative women, endocervical crypt involvement by CIN on pretreatment biopsies was associated with an almost fourfold risk of high-grade cytology recurrence following TA.²⁴ It has been postulated that crypt involvement by CIN may represent deeper or multifocal disease with a more aggressive potential of CIN associated with high-risk HPV.²³ Our study did not collect data on crypt involvement in pretreatment biopsies to evaluate this association, and it is unknown if endocervical crypt involvement by CIN is more common in WLWH and can help explain the higher CIN2/3 recurrence following TA. Longitudinal studies among WLWH undergoing TA in LMICs can evaluate whether presence of endocervical crypts impacts CIN2/3 recurrence.

Similarly, studies on the impact of lesion size and the type of transformation zone on TA treatment efficacy in LMICs are needed. The WHO criteria used in this study, recommends TA for Type 1 or Type 2 transformation zone where the TA probe tip will achieve complete ablation of the squamocolumnar junction. Inadequate fidelity to these guidelines in the context of screen & treat programs in LMICs which are not led by gynecologists or experienced colposcopists may impact observed efficacy rates.

This study's strength lies in using gold-standard histology diagnoses at baseline and follow-up to define CIN2/3 cases and ascertain cure, minimizing classification bias. However, limitations include a small sample size hindering identification of predictors of treatment failure, no HPV testing at follow-up inhibiting investigation of impact of HPV persistence on treatment failure, and lack of endocervical biopsies restricting our understanding of observed recurrences' relation to endocervical disease. Our 12-month follow-up rate of 84.3%, consistent with similar studies, could have validity implications due to potential differential loss-to-follow-up.

In conclusion, while hand-held TA devices are increasing access for cervical precancer treatment in LMICs, our results find higher CIN2/3 recurrence rates among WLWH than previously reported. This underscores a limitation of the current secondary prevention strategy in this high-risk group. Programs using TA must ensure robust follow-up protocols to identify and manage treatment failure among WLWH. Urgent research on innovative strategies, including adjuvant therapies to lower recurrence,²⁵ are needed to optimize treatment outcomes until more effective treatments are available.

Acknowledgments:

We thank the FACES Lumumba staff and leadership for support throughout this study as well as the study participants. Funding support from the Fogarty International Center of the National Institutes of Health (NIH) under Award Number D43TW009343 and the University of California Global Health Institute (UCGHI) and grant T32 MH19105 from the National Institutes of Mental Health of the U.S. Public Health Service.

Data availability:

De-identified data are available from the authors upon reasonable request.

Abbreviations:

CIN	cervical intraepithelial neoplasia
CIN2/3	cervical intraepithelial neoplasia grades 2 and 3
HPV	human papillomavirus
LMICs	Low- and middle-income countries
PEPFAR	President's Emergency Plan for AIDS Relief
SSA	sub-Saharan Africa
TA	Thermal ablation
VIA	visual inspection with acetic acid
WHO	World Health Organization
WLWH	women living with HIV

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–249. doi:10.3322/caac.21660 [PubMed: 33538338]
2. Castle PE, Einstein MH, Sahasrabudhe VV. Cervical cancer prevention and control in women living with human immunodeficiency virus. *CA Cancer J Clin.* 2021;71(6):505–526. doi:10.3322/caac.21696 [PubMed: 34499351]
3. World Health Organisation. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Published online 2013:1–40. www.who.int/about/licensing/copyright_form/en/index.html
4. Castle PE, Murokora D, Perez C, Alvarez M, Quek SC, Campbell C. Treatment of cervical intraepithelial lesions. *Int J Gynaecol Obstet Off organ Int Fed Gynaecol Obstet.* 2017;138 Suppl:20–25. doi:10.1002/ijgo.12191
5. (WHO) WHO. WHO Guidelines for the Use of Thermal Ablation for Cervical Pre-Cancer Lesions.; 2019.
6. Randall TC, Sauvaet C, Muwonge R, Trimble EL, Jeronimo J. Worthy of further consideration: An updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesions. *Prev Med (Baltim).* 2019;118(February 2018):81–91. doi:10.1016/j.ypmed.2018.10.006

7. Gordon HK, Duncan ID. Effective destruction of cervical intraepithelial neoplasia (CIN) 3 at 100 degrees C using the Semm cold coagulator: 14 years experience. *Br J Obstet Gynaecol.* 1991;98(1):14–20. doi:10.1111/j.1471-0528.1991.tb10304.x [PubMed: 1998626]
8. Campbell C, Kafwafwa S, Brown H, et al. Use of thermo-coagulation as an alternative treatment modality in a 'screen-and-treat' programme of cervical screening in rural Malawi. *Int J Cancer.* 2016;139(4):908–915. doi:10.1002/ijc.30101 [PubMed: 27006131]
9. Oga EA, Brown JP, Brown C, et al. Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women. *BMC Womens Health.* 2016;16(1):1–8. doi:10.1186/s12905-016-0304-8 [PubMed: 26729344]
10. Sauvaget C, Fayette J-M, Muwonge R, Wesley R, Sankaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. *Int J Gynaecol Obstet Off organ Int Fed Gynaecol Obstet.* 2011;113(1):14–24. doi:10.1016/j.ijgo.2010.10.012
11. Mungo C, Osongo CO, Ambaka J, et al. Safety and Acceptability of Thermal Ablation for Treatment of Human Papillomavirus Among Women Living With HIV in Western Kenya. *JCO Glob Oncol.* 2020;6:1024–1033. doi:10.1200/GO.20.00035 [PubMed: 32634066]
12. Hadzi B, Hadzi M, Curcin N. [Histologic classification and terminology of precancerous lesions of the cervix]. *Med Pregl.* 1999;52(3–5):151–155. [PubMed: 10518401]
13. Ragupathy K, Jayasinghe T, McMullen W. Thermal Ablation of High-Grade Premalignant Disease of the Cervix-Standing the Test of Time: A Retrospective Study. *J Low Genit Tract Dis.* 2022;26(1):27–31. doi:10.1097/LGT.0000000000000638 [PubMed: 34928251]
14. Loobuyck HA, Duncan ID. Destruction of CIN 1 and 2 with the Semm cold coagulator: 13 years' experience with a see-and-treat policy. *Br J Obstet Gynaecol.* 1993;100(5):465–468. doi:10.1111/j.1471-0528.1993.tb15273.x [PubMed: 8518248]
15. Joshi S, Muwonge R, Kulkarni V, et al. Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India. *Int J cancer.* 2023;152(2):249–258. doi:10.1002/ijc.34221 [PubMed: 35852007]
16. Pinder LF, Parham GP, Basu P, et al. Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial. *Lancet Oncol.* 2020;21(1):175–184. doi:10.1016/S1470-2045(19)30635-7 [PubMed: 31734069]
17. Tran PL, Kenfack B, Tincho Fogueu E, et al. Efficacy of thermoablation in treating cervical precancerous lesions in a low-resource setting. *Int J Womens Health.* 2017;9:879–886. doi:10.2147/IJWH.S142911 [PubMed: 29238232]
18. Kjør SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. *J Natl Cancer Inst.* 2010;102(19):1478–1488. doi:10.1093/jnci/djq356 [PubMed: 20841605]
19. Smith JS, Sanusi B, Swarts A, et al. A randomized clinical trial comparing cervical dysplasia treatment with cryotherapy vs loop electrosurgical excision procedure in HIV-seropositive women from Johannesburg, South Africa. *Am J Obstet Gynecol.* 2017;217(2):183.e1–183.e11. doi:10.1016/j.ajog.2017.03.022
20. Greene SA, De Vuyst H, John-Stewart GC, et al. Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya: A Randomized Clinical Trial. *JAMA.* 2019;322(16):1570–1579. doi:10.1001/jama.2019.14969 [PubMed: 31638680]
21. HADDAD NABIL, HUSSEIN IBRAHIM, BLESSING KAREN, KERR-WILSON RICHARD and GS. Tissue Destruction Following Cold Coagulation of the Cervix. *J Gynecol Surg.* 1988;4(1):23–27.
22. Taxa L, Jeronimo J, Alonzo TA, et al. Depth of Cervical Intraepithelial Neoplasia Grade 3 in Peruvian Women: Implications for Therapeutic Depth of Necrosis. *J Low Genit Tract Dis.* 2018;22(1):27–30. doi:10.1097/LGT.0000000000000355 [PubMed: 29271853]
23. Papoutsis D, Underwood M, Williams J, Parry-Smith W, Panikkar J. Expansile Endocervical Crypt Involvement by CIN2-3 as a Risk Factor for High Grade Cytology Recurrence After Cold Coagulation Cervical Treatment. *Geburtshilfe Frauenheilkd.* 2020;80(9):941–948. doi:10.1055/a-1202-2157 [PubMed: 32905285]

24. Papoutsis D, Underwood M, Parry-Smith W, Panikkar J. Risk factors for treatment failure following cold coagulation cervical treatment for CIN pathology: a cohort-based study. *Arch Gynecol Obstet.* 2015;292(6):1329–1337. doi:10.1007/s00404-015-3761-7 [PubMed: 26006259]
25. Maiman M, Watts DH, Andersen J, Clax P, Merino M, Kendall MA. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: A randomized trial. *Obstet Gynecol.* 1999;94(6):954–961. doi:10.1016/S0029-7844(99)00407-X [PubMed: 10576182]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Impact Statement:

In 2019, the World Health Organization endorsed Thermal Ablation (TA) as an alternative to cryotherapy for use within screen-and-treat programs in low- and middle-income countries. However, evidence on the efficacy of TA among women living with HIV (WLWH) is lacking. This study evaluates efficacy of thermal ablation among WLWH with biopsy-confirmed cervical intraepithelial neoplasia grade 2 and 3 (CIN2/3). Treatment failure at 12 months following TA was high, demonstrating a potential limitation of TA for use in WLWH.




Figure 1.
Participant Enrollment Flowchart.

Table 1:

Baseline demographics & clinical characteristics of HPV+/HIV+ women in Kenya who underwent thermal ablation by baseline pathology diagnosis

Characteristic	< CIN2 at baseline N=299)	CIN2 at baseline * N=77	P value **
Age (mean, SD) y	(39.9, 8.61)	(40.5, 8.22)	0.557
Marital status, n (%)			
Single	34 (11.4%)	6 (7.8%)	0.367
Married	136 (48.5%)	38 (49.3%)	
Widowed	81 (27.1%)	16 (20.8%)	
Divorced	48 (16.0%)	17 (22.1%)	
Highest education level attended, n (%)			
None	0 (0.0%)	0 (0.0%)	0.231
Primary	153 (52.4%)	42 (56.7%)	
Post-Primary/vocation	2 (0.7%)	0 (0.0%)	
Secondary	101 (34.6%)	23 (31.1%)	
Post-secondary	36 (12.3%)	9 (12.2%)	
Employment status, n (%)			
Employed	240 (80.3%)	64 (83.1%)	0.571
Not employed	59 (19.7%)	13 (16.9%)	
Daily household income, n (%)			
< 500 Kshs	191 (63.9%)	51 (66.2%)	0.691
500 Kshs	108 (36.1%)	26 (33.8%)	
Parity (mean, SD)	(3.3, 2.04)	(3.3, 2.81)	0.799
Age at first sexual intercourse (mean, SD)	(17.6, 3.26)	(17.6, 2.74)	0.899
Number of sexual partners (mean, SD)	(3.8, 3.24)	(4.0, 3.30)	0.608
CD4 count (mean, SD)	(442.9, 311.31)	(460.7, 276.05)	0.708
Virally suppressed, n (%)			
Yes	282 (97.6)	70 (97.2)	0.863
No	7 (2.4)	2 (2.8)	
Currently using contraception, n (%)			
Yes	124 (41.5%)	28 (36.4%)	0.109
No	175 (58.5%)	48 (62.3%)	
Don't know	0 (0.0%)	1 (1.3%)	
Method of contraception, n (%)			
Implant	64 (36.5%)	14 (29.2%)	0.477
Injectable	49 (28.0%)	15 (31.2%)	
Condoms	47 (26.9%)	16 (33.3%)	
Pills	10 (5.7%)	1 (2.1%)	
Other	5 (2.9%)	2 (4.2)	
Prior cervical cancer screening, n (%)			
Yes	217 (72.6%)	48 (62.3%)	0.214
No	79 (26.4%)	28 (36.4%)	

Characteristic	< CIN2 at baseline N=299)	CIN2 at baseline * N=77	P value **
Don't Know	3 (1.0%)	1 (1.3%)	
VIA result at screening, n (%)			
Positive	2 (0.9)	7 (11.3)	<0.0001
Negative	233 (99.1)	55 (88.7)	
Number of TA probe applications, n (%)			
1	248 (82.9)	56 (72.7)	0.003
>1	51 (17.1)	21 (27.3)	

*
14 CIN2, 56 CIN3, 7 invasive cancer

**
(t-test, chi-square or Fischer's exact test)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2:

Efficacy of thermal ablation for treatment of biopsy-confirmed CIN2/3 at 12-months among HIV-positive women in Kenya

Baseline pathology	Treatment success ¹ (cure) N (%), 95% CI	Treatment failure ² N (%), 95% CI
CIN2 or 3 (N=59)	39 (66.1%, 0.54, 0.782)	20 (33.9%, 0.22, 0.46)
CIN2 (N=13)	10 (76.9%, 0.54, 0.998)	3 (23.1%, 0.17–0.46)
CIN3 (N=46)	29 (63.04%, 0.49, 0.77)	17 (39.9%, 0.23, 0.51)

¹Regression to CIN1 or normal pathology on 12-month biopsy

²Persistence of CIN2 or higher on 12-month biopsy

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript